A Phase 2/3 Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma


NCT Number:



Study Status:






The purpose of this study is to evaluate the effectiveness and safety of an investigational drug, unesbulin. This investigational drug is being studied in unresectable or metastatic, relapsed or refractory leiomyosarcoma along with Dacarbazine. Dacarbazine is a drug that is FDA-approved for the treatment of other types of cancer and recommended by the cancer treatment guidelines for sarcomas, but is not FDA approved to treat leiomyosarcoma.

Are you Eligible? (Inclusion Criteria)

  • • You must be 18 years of age or older.
  • • You must have been previously diagnosed with advanced leiomyosarcoma.
  • • You must be comfortable swallowing pills.
  • • You must be comfortable with routine check- up procedures such as blood
  • sampling and tumor imaging to monitor cancer progression.

Specialty Area(s)

Sarcomas (Bone and Soft Tissue)

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032